163 related articles for article (PubMed ID: 19603021)
1. BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
Lee YK; Choi E; Kim MA; Park PG; Park NH; Lee H
Br J Cancer; 2009 Aug; 101(3):504-10. PubMed ID: 19603021
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
3. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients.
Chen YJ; Chen CM; Twu NF; Yen MS; Lai CR; Wu HH; Wang PH; Yuan CC
Virchows Arch; 2009 Nov; 455(5):431-40. PubMed ID: 19838728
[TBL] [Abstract][Full Text] [Related]
5. Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer.
McGrogan B; Phelan S; Fitzpatrick P; Maguire A; Prencipe M; Brennan D; Doyle E; O'Grady A; Kay E; Furlong F; McCann A
Hum Pathol; 2014 Jul; 45(7):1509-19. PubMed ID: 24792619
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary.
Werness BA; Freedman AN; Piver MS; Romero-Gutierrez M; Petrow E
Gynecol Oncol; 1999 Dec; 75(3):413-8. PubMed ID: 10600299
[TBL] [Abstract][Full Text] [Related]
10. Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue.
Yang Q; Zhao J; Cui M; Gi S; Wang W; Han X
J Obstet Gynaecol Res; 2015 Dec; 41(12):1959-64. PubMed ID: 26554540
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
12. KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
White NM; Mathews M; Yousef GM; Prizada A; Popadiuk C; Doré JJ
Br J Cancer; 2009 Oct; 101(7):1107-13. PubMed ID: 19707197
[TBL] [Abstract][Full Text] [Related]
13. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
14. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
16. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
[TBL] [Abstract][Full Text] [Related]
17. Recurrence season impacts the survival of epithelial ovarian cancer patients.
Liu XH; Man YN; Wu XZ
Asian Pac J Cancer Prev; 2014; 15(4):1627-32. PubMed ID: 24641379
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer.
Son JH; Kong TW; Paek J; Song KH; Chang SJ; Ryu HS
Int J Gynaecol Obstet; 2017 Dec; 139(3):352-357. PubMed ID: 28857180
[TBL] [Abstract][Full Text] [Related]
19. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression.
Bi R; Shen X; Zhang W; Cheng Y; Feng Z; Cai X; Yang W
Diagn Pathol; 2016 Feb; 11():17. PubMed ID: 26837693
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and survival analyses of synchronous primary endometrial and epithelial ovarian cancers.
Sozen H; Vatansever D; Iyibozkurt AC; Topuz S; Ozsurmeli M; Salihoglu Y; Guzelbey B; Berkman S
J Obstet Gynaecol Res; 2015 Nov; 41(11):1813-9. PubMed ID: 26369625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]